Browse the evidence

Life expectancy in the United States has decelerated over the past 30 years compared to historical patterns.

Practitioners should be aware of the slowing growth in life expectancy when planning for health interventions.

Predictions suggest that life expectancy will continue to rise throughout this century due to advances in biomedical technology.

Health policymakers should consider potential future increases in life expectancy when designing age-related programs.

Some researchers predict that aging itself will soon be mastered by science, allowing people to live well beyond 100 years.

Practitioners should prepare for potential breakthroughs in aging research that could extend lifespan significantly.

BGM1812 was developed through a step-by-step modification process guided by structure-based drug design and molecular dynamics simulations.

Understanding the development process can inform future drug design strategies.

The study highlights a persistently elevated pulmonary aspiration risk in patients receiving semaglutide.

Anesthesiologists should be cautious of the increased aspiration risk in patients on semaglutide during surgery.

Up to 40% of adults in the United States have metabolic dysfunction-associated steatotic liver disease (MASLD).

Practitioners should be aware of the high prevalence of MASLD in adult patients.

Metabolic dysfunction-associated steatohepatitis is now a leading indication for liver transplantation.

Healthcare providers should consider MASLD as a critical factor in liver transplant evaluations.

GLP-1 receptor-based agonists and oral dipeptidyl peptidase-4 inhibitors are currently the only available treatments for metabolic diseases.

Practitioners should be aware that current treatment options are limited to GLP-1 receptor-based therapies.

Current GLP-1-based therapies face challenges such as high costs and the need for repeated administration.

Healthcare providers should consider these challenges when prescribing GLP-1 therapies.

Research is ongoing to develop improved GLP-1-based therapies, including oral small-molecule agonists and novel drug delivery strategies.

Practitioners should stay informed about emerging GLP-1 therapies that may improve patient compliance.

The quality of existing clinical evidence from anti-obesity trials generally ranges from low to moderate.

Practitioners should be cautious in interpreting the effectiveness of current anti-obesity medications due to the low to moderate quality of evidence.

Most trials suffered from publication bias.

Practitioners should be aware of potential biases in the published literature on anti-obesity drugs.

Additional higher-quality clinical trials are needed to gain more confidence in the estimate of the effect of currently used anti-obesity medicines.

Practitioners should advocate for and support the conduct of higher-quality trials to improve treatment options for obesity.

There is a better understanding of biomolecules related to obesity, including gut hormones and fat utilization.

Practitioners should consider the role of biomolecules in obesity management.

Tirzepatide effectively attenuated the rewarding properties of alcohol, measured through locomotor stimulation, conditioned place preference, and accumbal dopamine release.

Tirzepatide may be a potential treatment for reducing alcohol consumption and its rewarding effects.

18F-FDG PET scanning is the most commonly used imaging modality to detect and quantify human BAT activity in vivo.

Clinicians can utilize 18F-FDG PET for assessing BAT activity in patients.

Alternative PET tracers and novel techniques have improved understanding of human BAT physiology.

Emerging imaging techniques can enhance research and clinical understanding of BAT's role in health.

Plasma GLP-1 and PYY responses do not differ between individuals with obesity and lean controls.

This suggests that obesity does not affect the immediate hormonal response of GLP-1 and PYY to a meal.

Tissue concentrations and mRNA expression of GLP-1 and PYY do not differ between individuals with obesity and lean controls.

This indicates that obesity does not alter the local production of GLP-1 and PYY in the gut.

GLP-1 medicines may suppress tumorigenesis through various mechanisms.

Further research is needed to understand the mechanisms by which GLP-1 medicines may affect tumorigenesis.

GLP-1 RA therapy was associated with a low rate of major adverse events in LVAD patients.

GLP-1 RA appears to be a safe adjunct therapy for LVAD patients.

Individuals with Friedreich's ataxia (FRDA) have lower insulin sensitivity (whole-body insulin sensitivity index 2.8 vs 5.3, P < .01) compared to controls.

Practitioners should be aware that FRDA is associated with reduced insulin sensitivity, which may impact metabolic health.

Ongoing research is crucial to confirm the long-term safety, effectiveness, and clinical role of these agents.

Practitioners should stay updated on research developments regarding these oral agents.

GLP-1 RA therapy was not associated with increased incidence of GI cancers.

GLP-1 RAs may be a safer option regarding GI cancer risk for patients with type 2 diabetes.